A Trio of Uses for Mometasone Furoate

A Trio of Uses for Mometasone Furoate

asthmaMometasone Furoate, CAS# 83919-23-7 is in the class of drugs known as corticosteroids, there are several products in which mometasone furoate is efficacious. For the treatment of asthma, mometasone furoate may also be known by the brand name Asmanex Twisthaler. Offered in powder form, inhalation 110 mcg/actuation or 220 mcg/actuation, mometasone furoate relieves asthmatic symptoms by decreasing swelling and irritation in the airways of patients. In addition, it may be useful in preventing breathing difficulties and chest tightness, as well as wheezing, and coughing caused by asthma. While mometasone furoate should not be used to treat an acute asthma attack, it is a formidable solution for controlling asthma in affected patients. Mometasone works best if it is inhaled at the same time daily, either once or twice a day as prescribed. Side effects may include heartburn, headache, stomach pain, vomiting, dry throat and nosebleeds. The patent for the use of mometasone furoate for the treatment of lower airway passage and lung diseases is expiring January 27, 2014, paving way for generic equivalents for treating the ever growing population of patients with asthma. asthma-diagnosis-chartAccording to The American Academy of Allergy, Asthma & Immunology, the number of people with asthma in the United States is steadily growing. For example, in 2001, 1 in 14 Americans had been diagnosed with asthma, or about 7% of the population. As of 2009 1 in 12 people, or 8% of the U.S. population has an asthma diagnosis. Additionally an estimated 300 million people worldwide are currently projected to suffer from asthma, causing 250,000 annual deaths. Treatment with inhaled corticosteroids, such as the popular asthma drug Dulera (formoterol/mometasone) has certainly offered viable solutions for this large patient population.

asthma-triggersAllergic rhinits and seasonal allergies are vastly problematic, and mometasone furoate meets the need for treatment in the form of an intranasal spray. Known by the brand name Nasonex and available in a 50 mcg size, mometasone furoate is effectual when used by patients once daily, either one or two sprays in each nostril. Side effects may include sore throat, cough, vomiting and headache. As a nasal inhalation treatment mometasone is often a preferable option for patients who don’t want to experience side effects of typical oral allergy medications. With allergic diseases affecting 40 to 50 million Americans, according to The American Academy of Allergy, Asthma & Immunology, continued research using mometasone furoate is essential.

Mometasone FuroateKnown as brand names Elocon and Momexin, mometasone furoate is also available in topical cream, ointment and lotion formations. Typically prescribed to patients suffering from eczema, atopic dermatitis, psoriasis, contact dermatitis, seborrhea and poison ivy, mometasone furoate is quite versatile. Adverse effects are few, but may include skin irritation, dryness and itching.

Effective for treating conditions such as asthma, allergic rhinitis, and inflammatory skin conditions, mometasone furoate is offered for research and development in several forms. LGM Pharma is a provider of mometasone furoate, and offers complete support to clients throughout the R&D process. Inquire about US-DMF , E-DMF / CTD, CEP (CoS) for this API product. This API is also available as a TEVA API (TAPI) for compounding purposes in the US.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service